Evidence map›Paper›PMID 41782706›Full record

ArticleCase reports in oncology

Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases.

Aneeqa Zafar, Hanna Yakubi, Benjamin Moskoff, Kathryn Alvarez, Amber Tang, Joseph Tuscano, Aaron Rosenberg

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aneeqa ZafarDepartment of Hematology Oncology, University of California Davis, Sacramento, CA, USA.
Hanna YakubiDepartment of Pharmacy, University of California Davis, Sacramento, CA, USA.
Benjamin MoskoffDepartment of Pharmacy, University of California Davis, Sacramento, CA, USA.
Kathryn AlvarezDepartment of Pharmacy, University of California Davis, Sacramento, CA, USA.
Amber TangDepartment of Pharmacy, University of California Davis, Sacramento, CA, USA.
Joseph TuscanoDivision of Malignant Hematology and Cellular Therapy, University of California Davis, Sacramento, CA, USA.
Aaron RosenbergDivision of Malignant Hematology and Cellular Therapy, University of California Davis, Sacramento, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS. Case Presentation: We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up. Conclusion: These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.

Indexed as

Central nervous system lymphomaEnd-stage renal diseaseHemodialysisHigh-dose methotrexateMethotrexate clearance

Identifiers

PMID41782706
PMCPMC12956320

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.